Neuren Pharmaceuticals (NEU) Study Result summary

Meeting context and regulatory progress

• Achieved positive and collaborative outcomes from the end of phase II meeting with the FDA for Phelan-McDermid Syndrome, marking the first-ever pivotal trial proposal for this condition.

• Alignment reached with FDA on pivotal phase III trial design, dose, duration, and population, with only efficacy endpoints pending final confirmation after submission of additional data.

• The FDA meeting focused heavily on efficacy endpoint options, reflecting the lack of precedent and validated measures for this syndrome.

• The process is iterative, with ongoing dialogue and no set deadline for endpoint agreement, but both parties are working rapidly.

• PMS is a rare disorder with no approved therapies, causing severe developmental and quality of life impacts; NNZ-2591 aims to address this unmet need.

Pivotal trial design and operational plans

• The pivotal trial will be a single, randomized, double-blind, placebo-controlled study in children aged 3–12, with 13 weeks of treatment and an open-label extension until commercial launch.

• The trial's dose, duration, and population closely mirror the phase II program, and a less burdensome safety monitoring scheme has been agreed in principle, pending FDA protocol review.

• Preparations include ongoing site identification, patient engagement with advocacy groups, and manufacturing of NNZ-2591 at commercial-scale suppliers.

• The number of trial participants will exceed 100, with final numbers dependent on endpoint agreement.

• Manufacturing is well underway and not a limiting factor for trial initiation.

Financial and strategic outlook

• Estimated phase III trial costs remain at $50–100 million USD, with over $200 million in cash and additional milestone payments expected.

• The company is considering share buybacks and capital management options, supported by a strong cash position and ongoing revenue from DAYBUE.

• No immediate plans for dividends; focus remains on maximizing value from NNZ-2591 and potential new indications.

• Interest in partnerships continues, but management believes greater value lies in advancing to a positive phase III result.

• The long-term strategy is to capture maximum value from NNZ-2591, with openness to future commercialization or partnerships.